Compare Sun Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ALKEM LABORATORIES - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ALKEM LABORATORIES SUN PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 28.4 - - View Chart
P/BV x 2.9 8.2 35.1% View Chart
Dividend Yield % 0.6 0.5 105.0%  

Financials

 SUN PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
ALKEM LABORATORIES
Mar-16
SUN PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6791,589 42.7%   
Low Rs3751,232 30.5%   
Sales per share (Unadj.) Rs121.1417.5 29.0%  
Earnings per share (Unadj.) Rs13.456.3 23.8%  
Cash flow per share (Unadj.) Rs20.764.7 32.0%  
Dividends per share (Unadj.) Rs2.7512.70 21.7%  
Dividend yield (eoy) %0.50.9 57.9%  
Book value per share (Unadj.) Rs172.6292.9 58.9%  
Shares outstanding (eoy) m2,399.26119.57 2,006.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.4 128.8%   
Avg P/E ratio x39.425.1 157.3%  
P/CF ratio (eoy) x25.521.8 116.9%  
Price / Book Value ratio x3.14.8 63.4%  
Dividend payout %20.622.6 91.1%   
Avg Mkt Cap Rs m1,264,650168,653 749.9%   
No. of employees `00017.5NA-   
Total wages/salary Rs m59,6719,171 650.6%   
Avg. sales/employee Rs Th16,608.1NM-  
Avg. wages/employee Rs Th3,409.6NM-  
Avg. net profit/employee Rs Th1,833.8NM-  
INCOME DATA
Net Sales Rs m290,65949,915 582.3%  
Other income Rs m10,2551,645 623.4%   
Total revenues Rs m300,91451,561 583.6%   
Gross profit Rs m63,0768,482 743.6%  
Depreciation Rs m17,5331,006 1,743.1%   
Interest Rs m5,553671 828.0%   
Profit before tax Rs m50,2468,451 594.6%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0091,606 374.1%   
Profit after tax Rs m32,0936,731 476.8%  
Gross profit margin %21.717.0 127.7%  
Effective tax rate %12.019.0 62.9%   
Net profit margin %11.013.5 81.9%  
BALANCE SHEET DATA
Current assets Rs m310,69227,062 1,148.1%   
Current liabilities Rs m173,39615,324 1,131.6%   
Net working cap to sales %47.223.5 200.9%  
Current ratio x1.81.8 101.5%  
Inventory Days Days9967 148.9%  
Debtors Days Days11241 270.3%  
Net fixed assets Rs m232,47712,610 1,843.7%   
Share capital Rs m2,399239 1,003.5%   
"Free" reserves Rs m411,69134,490 1,193.7%   
Net worth Rs m414,09135,027 1,182.2%   
Long term debt Rs m15,2261,212 1,256.7%   
Total assets Rs m646,93854,387 1,189.5%  
Interest coverage x10.013.6 73.9%   
Debt to equity ratio x00 106.3%  
Sales to assets ratio x0.40.9 49.0%   
Return on assets %5.813.6 42.8%  
Return on equity %7.819.2 40.3%  
Return on capital %10.224.9 40.9%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m66,0256,563 1,006.0%   
Fx outflow Rs m38,6103,012 1,282.0%   
Net fx Rs m27,4153,552 771.9%   
CASH FLOW
From Operations Rs m21,9657,259 302.6%  
From Investments Rs m-6,8131,864 -365.4%  
From Financial Activity Rs m-27,305-9,273 294.5%  
Net Cashflow Rs m-8,442-150 5,627.7%  

Share Holding

Indian Promoters % 63.7 66.9 95.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 33.1 15.5%  
FIIs % 23.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 0.0 -  
Shareholders   133,026 68,381 194.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Telecom Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended higher, tracking positive global sentiments.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

The Best Safe Investment for Senior Citizens(Fast Profits Daily)

Jun 4, 2020

With Interest rates near record lows, there is a safe investment which still pays a decent interest.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 5, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS